Chief Commercial Officer

The Biosimilar
Invasion

Three biosimilars have landed. They are capturing your market segments one by one.

Market Segment Invasion Map

Watch biosimilars capture your territory in real-time

Your Market Share
65%
Commercial
$505M
Medicare
$439M
Medicaid
$317M
VA/DoD
$696M
340B
$259M
Specialty
$423M
INVADERS
BioSim-A
-35% discount
BioSim-B
-42% discount
BioSim-C
-38% discount

The Invasion Strategy

Price Assault

Biosimilars launch at 35% discount. Then 40%. Then 50%. Each new entrant undercuts the last, and payers demand you match or lose the business.

Payer Defection

Medicare switched to preferred biosimilar. Medicaid followed. Now your largest commercial PBMs are threatening step-through requirements.

Multi-Front War

Three biosimilars coordinate their attacks. As you defend one segment, another falls. Your resources are stretched across too many fronts.

The Biosimilar Battlefield

$100B
biologics market under biosimilar attack
45%
avg share lost to biosimilars in 3 years
-38%
average biosimilar discount
3-7
biosimilars per major biologic

Mount Your Defense

SlideStrike transforms biosimilar competitive data into defensive strategy dashboards that protect your market segments.

Intelligence

Invasion Radar

Track biosimilar contract wins, formulary changes, and share shifts in real-time. Know which segments are under attack before you lose them.

See Radar Demo
Strategy

Defense Optimizer

Model defensive scenarios: discount matching, patient programs, and segment prioritization. Know which battles to fight and which to cede.

See Defense Demo

Biosimilar Defense FAQ

QHow fast do biosimilars capture market share?

Biosimilars typically capture 30-50% of the market within 2 years of launch. In price-sensitive segments like Medicare and Medicaid, penetration can reach 70% within 18 months.

QWhat discounts do biosimilars typically offer?

Initial biosimilar discounts range from 15-35% off the reference product. With multiple biosimilar competitors, discounts can reach 40-60% as companies compete for payer contracts.

QCan branded biologics defend against biosimilars?

Defense strategies include: contracted discounts to match biosimilars, differentiated formulations (SC vs IV), patient support programs, and KOL education on interchangeability concerns.

QWhich market segments are most vulnerable?

Government payers (Medicare, Medicaid, VA) switch fastest due to cost mandates. Commercial plans follow as biosimilars achieve interchangeability status. Specialty pharmacies often convert last.

Defend Your Territory.

See how SlideStrike helps CCOs build and execute biosimilar defense strategies.

Request Biosimilar Defense Demo